Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026
Rhea-AI Summary
Beyond Cancer (NASDAQ: XAIR) was selected to present Phase 1 data on intratumoral ultra-high concentration nitric oxide (UNO) in solid tumor metastases at the AACR Annual Meeting 2026 in San Diego.
The abstract will be presented April 19, 2026 (Poster Section 13, Poster Board 22, Poster Number 304) and the itinerary text is scheduled for online publication March 17, 2026 at 4:30 PM ET.
Positive
- None.
Negative
- None.
News Market Reaction – XAIR
On the day this news was published, XAIR declined 5.22%, reflecting a notable negative market reaction. Argus tracked a trough of -6.1% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $20.55M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed moves (e.g., DHAI +400%, NVNO -7.34%), and no peers appear in momentum scans, suggesting this AACR abstract news is stock-specific rather than part of a coordinated sector move.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2025-09-08 | Orphan drug designation | Positive | +49.8% | FDA Orphan Drug Designation for BA-101 in glioblastoma. |
| 2024-12-03 | Phase 1b trial approval | Positive | -8.7% | Israeli approval for Phase 1b LV UNO plus anti-PD-1 trial. |
| 2024-11-11 | Preclinical LV UNO data | Positive | +7.6% | Promising LV UNO preclinical efficacy at SITC 2024. |
| 2024-07-31 | Clinical pneumonia data | Positive | -5.2% | Peer-reviewed data on nitric oxide in viral pneumonia. |
| 2024-06-03 | Phase 1a UNO data | Positive | -8.6% | First-in-class Phase 1a UNO data in solid tumors. |
Clinical and trial-related announcements have often been positive in content but produced mixed price reactions, with more instances of negative than positive moves.
Over the past year, XAIR has issued several clinically focused updates, including FDA Orphan Drug Designation for glioblastoma on 2025-09-08 and multiple nitric oxide–based clinical and preclinical data readouts. These have included Phase 1 data in unresectable solid tumors and peer‑reviewed publication of viral pneumonia results. Price reactions to these clinical updates have been inconsistent, with some strong gains and several notable declines. The current AACR Phase 1 abstract fits into this ongoing development of the nitric oxide oncology platform.
Historical Comparison
Clinical trial–tagged news for XAIR has produced an average move of about 7%, with reactions ranging from sharp gains to meaningful declines, indicating unstable sentiment around clinical milestones.
Clinical news has progressed from early UNO Phase 1a data and preclinical LV UNO results to trial approvals and Orphan Drug Designation, with the current AACR Phase 1 metastases abstract extending the oncology nitric oxide narrative.
Regulatory & Risk Context
An active Form S-3 shelf dated 2026-01-30 allows resale of 524,990 existing common shares plus additional shares from pre-funded and common warrants. Beyond Air would not receive proceeds from stockholder resales but would receive cash upon warrant exercises, with common warrants exercisable at $1.147 through January 16, 2031.
Market Pulse Summary
The stock moved -5.2% in the session following this news. A negative reaction despite clinically oriented news fits past patterns, where three of five clinical-trial-tagged announcements led to declines, including moves of -8.59% and -8.67%. The stock traded well below its $2.54 200-day moving average before this AACR abstract, and recent financing activity plus an active S-3 shelf for resale and warrant exercises may add to perceived overhang, amplifying downside reactions to otherwise constructive clinical milestones.
Key Terms
intratumoral medical
nitric oxide medical
metastases medical
AI-generated analysis. Not financial advice.
GARDEN CITY, N.Y., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors and subsidiary of Beyond Air, Inc. (NASDAQ: XAIR), today announced being selected to present an abstract featuring data from the Phase 1 trial of intratumoral UNO in solid tumor metastases at the American Association for Cancer Research (AACR) Annual Meeting 2026, which is scheduled to be held from Friday, April 17th, through Wednesday, April 22nd, at the San Diego Convention Center in San Diego, California. The original submitted abstract titles and text are scheduled to be published in an Online Itinerary Planner on March 17, 2026 at 4:30 PM ET / 1:30 PM PT.
| AACR Annual Meeting 2026 Abstract Details: | ||
| Presenter: | Amichay Meirovitz, MD, Soroka University Medical Center, Beersheba, Israel | |
| Session Category: | Experimental and Molecular Therapeutics | |
| Session Title: | Innovative Therapeutic Modalities and Translational Platforms | |
| Session Start: | April 19, 2026 at 5:00 PM ET / 2:00 PM PT | |
| Session End: | April 19, 2026 at 8:00 PM ET / 5:00 PM PT | |
| Location: | Poster Section 13, San Diego Convention Center | |
| Poster Board Number: | 22 | |
| Poster Number: | 304 | |
About Beyond Cancer, Ltd.
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc., is a development-stage biopharmaceutical and medical device company utilizing (UNO via a proprietary delivery platform to treat primary tumors and prevent metastatic disease. Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer. A first-in-human study is underway in subjects with solid tumors. The Company is conducting preclinical studies of UNO in multiple solid tumor models to inform additional treatment protocols. For more information, visit www.beyondcancer.com.
About Beyond Air®, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).
The Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.
About LungFit *
Beyond Air's LungFit is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders, providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety by eliminating NO2 purging steps, and offering other operational benefits.
LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.
*Beyond Air's LungFit PH is approved for commercial use in the United States, European Union, and many other countries around the world. Beyond Air's other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.
Forward Looking Statements
This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.
CONTACTS:
Investor Relations contacts
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
FAQ
When will Beyond Cancer (XAIR) present Phase 1 UNO data at AACR 2026?
Where and how can investors view Beyond Cancer's (XAIR) AACR 2026 abstract and presentation?
Who is the presenter for Beyond Cancer's (XAIR) AACR 2026 poster on UNO therapy?
What session will Beyond Cancer's (XAIR) UNO abstract appear in at AACR Annual Meeting 2026?
